Milad Rezvani, M.D.
- Resident, Boston Children's Hospital
Contact Information
University of California San Francisco
35 Medical Center Way
RMB-902D, Pod A
San Francisco, CA 94143
Lab phone: 415 476 2420
Cell phone: 415 933 9238
[email protected]
Education
Wilhelm-Raabe-Schule, Lower Saxony, Hannover, Germany, University-entrance diploma, 2004
Hannover Medical School, Germany, Preclinical Medical Examination, 2006
University of Freiburg, Germany, German Medical State Examination, 2011
04/2015 - 08/2016 Clinical guest student at USCF Medical Center at Mission Bay, Pediatric Hepatology and San Francisco General Hospital, Adult GI division
University of Freiburg, Germany, Doctoral Dissertation, "Role of Matrix Metalloproteinases in the genetics of Bronchopulmonary Dysplasia and Neonatal Respiratory Distress Syndrome", 2013
Biomedical Exchange Program (BMEP)-Scholarship funded by the German Academic Exchange Service (DAAD) for research on liver cell therapy at the Willenbring lab at the University of California San Francisco (UCSF), 2012-2013
Fellowships
- Biomedical Exchange Program (BMEP)-Scholarship funded by the German Academic Exchange Service (DAAD), Research Fellowship of the German Research Foundation
Postdoctoral Training
- Willenbring laboratory, Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, UCSF, Research Foci: 1. Therapeutic liver repopulation with hepatocytes generated from human fibroblasts, 2. In vivo hepatic reprogramming of myofibroblasts in liver fibrosis and cirrhosis
Biography
Milad Rezvani, M.D. studied Medicine in Hannover/Germany and Freiburg/Germany and also worked as a volunteer in numerous Primary Health Care projects in Ghana, Nepal, Peru and Argentina. As a graduate student he investigated the effect of genetic variants in endoderm and lung development on neonatal lung diseases. As an exchange student he came to UCSF to work on generating therapeutic human liver cells from readily available skin cells. As a Postdoctoral Fellow of the German Research Foundation he continued working in the Willenbring lab to develop potential therapies for chronic liver diseases, particularly by in vivo reprogramming of cirrhosis-causing myofibroblasts into hepatocytes.
Posters & Oral Presentations
- 11/2015: Presidential Plenary Session of the The Liver Meeting of the American Association for the Study of Liver Diseases (AASLD), San Francisco, CA, selected oral presentation: "In vivo reprogramming of myofibroblasts into hepatocytes as a therapy for liver fibrosis"
In the News
- Willenbring Lab - - June 03, 2016UCSF News reports on the research of the Willenbring Lab and others demonstrating in mice that healthy new liver cells could be generated within the organ itself, thus making engraftment unnecessary. The article noted that the very cells that drive liver disease were converted, thereby reducing liver damage and improving liver function simultaneously. The study was recently reported on in a paper published by the journal Cell Stem Cell. Advances in stem cell research have made it possible [...]
